{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T03:30:16Z","timestamp":1777174216802,"version":"3.51.4"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Project of Ministry of Education, Science and Technological Development, Republic of Serbia","award":["Grant 41012"],"award-info":[{"award-number":["Grant 41012"]}]},{"name":"Project for Scientific and Technological Development of Vojvodina","award":["114-451-2072-\/2016-02"],"award-info":[{"award-number":["114-451-2072-\/2016-02"]}]},{"name":"Horizon2020 MEDLEM project","award":["690876"],"award-info":[{"award-number":["690876"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.phrs.2019.104333","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T12:08:23Z","timestamp":1561550903000},"page":"104333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Semisynthetic bile acids: a new therapeutic option for metabolic syndrome"],"prefix":"10.1016","volume":"146","author":[{"given":"Slavica","family":"Lazarevi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"\u0110ani\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Golo\u010dorbin-Kon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Al-Salami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momir","family":"Mikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.phrs.2019.104333_bib0005","doi-asserted-by":"crossref","first-page":"e2096","DOI":"10.1038\/cddis.2016.19","article-title":"Caspase-2 promotes obesity, the metabolic syndrome and nonalcoholic fatty liver disease","volume":"7","author":"Machado","year":"2017","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.phrs.2019.104333_bib0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1440-1746.2010.06253.x","article-title":"A fresh look at NASH pathogenesis. Part 1: the metabolic movers","volume":"25","author":"Larter","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104333_bib0015","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.dld.2010.01.016","article-title":"From the metabolic syndrome to NAFLD or vice versa?","volume":"42","author":"Vanni","year":"2010","journal-title":"Dig. Liver Dis."},{"issue":"6037","key":"10.1016\/j.phrs.2019.104333_bib0020","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.1204265","article-title":"Human fatty liver disease: old questions and new insights","volume":"332","author":"Cohen","year":"2011","journal-title":"Science."},{"issue":"2","key":"10.1016\/j.phrs.2019.104333_bib0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.metabol.2013.10.002","article-title":"Type 1 diabetes, metabolic syndrome and cardiovascular risk","volume":"63","author":"Chillaron","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2019.104333_bib0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.phrs.2015.03.002","article-title":"Hepatic steatosis after islet transplantation: can ultrasound predict the clinical outcome? A longitudinal study in 108 patients","volume":"98","author":"Venturini","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.phrs.2019.104333_bib0035","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00592-015-0735-y","article-title":"Co-transplantation of autologous MSCs delays islet allograft rejection and generates a local immunoprivileged site","volume":"52","author":"Ben Nasr","year":"2015","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.phrs.2019.104333_bib0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.phrs.2014.07.004","article-title":"The rise, fall, and resurgence of immunotherapy in type 1 diabetes","volume":"98","author":"Ben Nasr","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0045","first-page":"18","article-title":"Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases","volume":"14","author":"Stanimirov","year":"2015","journal-title":"HBPD INT"},{"issue":"7","key":"10.1016\/j.phrs.2019.104333_bib0050","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease","volume":"152","author":"Ch\u00e1vez-Talavera","year":"2017","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.phrs.2019.104333_bib0055","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1194\/jlr.R024794","article-title":"Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease","volume":"53","author":"Porez","year":"2012","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tem.2017.11.002","article-title":"Role of bile acids in metabolic control","volume":"29","author":"Molinaro","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"issue":"13","key":"10.1016\/j.phrs.2019.104333_bib0065","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4239\/wjd.v7.i13.260","article-title":"Role of bile acids in the regulation of the metabolic pathways","volume":"7","author":"Taoka","year":"2016","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.phrs.2019.104333_bib0070","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3389\/fphar.2018.01382","article-title":"Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome","volume":"9","author":"\u0110ani\u0107","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0075","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1530\/JOE-15-0469","article-title":"The role of bile acids in metabolic regulation","volume":"228","author":"V\u00edtek","year":"2016","journal-title":"J. Endocrinol."},{"issue":"18","key":"10.1016\/j.phrs.2019.104333_bib0080","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1021\/jm070633p","article-title":"Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23-and 6, 23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5","volume":"50","author":"Pellicciari","year":"2007","journal-title":"J. Med. Chem."},{"issue":"1-2","key":"10.1016\/j.phrs.2019.104333_bib0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijpharm.2012.04.077","article-title":"Effect of ketocholate derivatives on methotrexate uptake in Caco-2 cell monolayers","volume":"433","author":"Chen","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.phrs.2019.104333_bib0090","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1211\/jpp.61.07.0016","article-title":"Monoketocholate can decrease transcellular permeation of methotrexate across Caco\u20102 cell monolayers and reduce its intestinal absorption in rat","volume":"61","author":"Chen","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104333_bib0095","series-title":"An Illustrated Chinese Materia Medica","author":"Wu","year":"2005"},{"key":"10.1016\/j.phrs.2019.104333_bib0100","series-title":"Chinese Materia Medica: Chemistry, Pharmacology and Applications","author":"Zhu","year":"1998"},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0105","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1746-4269-5-2","article-title":"Bear bile: dilemma of traditional medicinal use and animal protection","volume":"5","author":"Feng","year":"2009","journal-title":"J. Ethnobiol. Ethnomed."},{"issue":"5418","key":"10.1016\/j.phrs.2019.104333_bib0110","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"issue":"5418","key":"10.1016\/j.phrs.2019.104333_bib0115","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.phrs.2019.104333_bib0120","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/pr.113.008201","article-title":"Bile acid signaling in metabolic disease and drug therapy","volume":"66","author":"Li","year":"2014","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2019.104333_bib0125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/10799893.2013.802805","article-title":"The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders","volume":"33","author":"Stepanov","year":"2013","journal-title":"J. Recept. Signal Transduct. Res."},{"issue":"2","key":"10.1016\/j.phrs.2019.104333_bib0130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrd4545","article-title":"FDA drug approvals","volume":"14","author":"Mullard","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9184","key":"10.1016\/j.phrs.2019.104333_bib0135","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.phrs.2019.104333_bib0140","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrd2619","article-title":"Targeting bile-acid signalling for metabolic diseases","volume":"7","author":"Thomas","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2019.104333_bib0145","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.R024794","article-title":"Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease","author":"Porez","year":"2012","journal-title":"J. Lipid Res."},{"issue":"12","key":"10.1016\/j.phrs.2019.104333_bib0150","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-016-0616-x","article-title":"Obeticholic acid: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0155","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2003.11.006","article-title":"Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms","volume":"40","author":"Chiang","year":"2004","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.phrs.2019.104333_bib0160","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","article-title":"Bile acids: regulation of synthesis","volume":"50","author":"Chiang","year":"2009","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0165","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/3034","article-title":"A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis","volume":"20","author":"Strautnieks","year":"1998","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.phrs.2019.104333_bib0170","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1152\/physrev.00027.2002","article-title":"Bile salt transporters: molecular characterization, function, and regulation","volume":"83","author":"Trauner","year":"2003","journal-title":"Physiol. Rev."},{"issue":"10","key":"10.1016\/j.phrs.2019.104333_bib0175","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1073\/pnas.0712328105","article-title":"The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis","volume":"105","author":"Rao","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2019.104333_bib0180","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.2741\/3416","article-title":"OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids","volume":"14","author":"Ballatori","year":"2009","journal-title":"Front Biosci."},{"issue":"201","key":"10.1016\/j.phrs.2019.104333_bib0185","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-642-14541-4_4","article-title":"Role of the intestinal bile acid transporters in bile acid and drug disposition","author":"Dawson","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0190","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"Russell","year":"2003","journal-title":"Annu. Rev. Biochem."},{"issue":"14","key":"10.1016\/j.phrs.2019.104333_bib0195","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3748\/wjg.15.1677","article-title":"Bile-acid-induced cell injury and protection","volume":"15","author":"Perez","year":"2009","journal-title":"World J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.phrs.2019.104333_bib0200","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1016\/S0021-9258(18)32418-9","article-title":"The influence of bile salt structure on self-association in aqueous solutions","volume":"258","author":"Roda","year":"1983","journal-title":"J. Biol. Chem."},{"issue":"7059","key":"10.1016\/j.phrs.2019.104333_bib0205","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/nature04162","article-title":"Interfaces and the driving force of hydrophobic assembly","volume":"437","author":"Chandler","year":"2005","journal-title":"Nature"},{"issue":"1-2","key":"10.1016\/j.phrs.2019.104333_bib0210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cocis.2009.11.010","article-title":"Self-assembly in aqueous bile salt solutions","volume":"15","author":"Madenci","year":"2010","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.phrs.2019.104333_bib0215","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3389\/fphar.2018.01283","article-title":"Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles","volume":"9","author":"Pavlovi\u0107","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104333_bib0220","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.phrs.2018.12.008","article-title":"Idebenone and T2D: a new insulin-sensitizing drug for personalized therapy","volume":"139","author":"Dassano","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"3-4","key":"10.1016\/j.phrs.2019.104333_bib0225","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/21553769.2013.879925","article-title":"Application of bile acids in drug formulation and delivery","volume":"7","author":"Stojan\u010devi\u0107","year":"2013","journal-title":"Front. Life Sci."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0230","first-page":"553","article-title":"Docking-based preliminary study on the interactions of bile acids with drugs at the transporter level in intestinal bacteria","volume":"20","author":"Djanic","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0235","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF03190714","article-title":"Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents","volume":"31","author":"Mikov","year":"2006","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.phrs.2019.104333_bib0240","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s13318-016-0375-9","article-title":"Mixed micelles loaded with bile salt: an approach to enhance intestinal transport of the BCS class III drug cefotaxime in rats","volume":"42","author":"Arafat","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.phrs.2019.104333_bib0245","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0250","first-page":"72","article-title":"Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors","volume":"9","author":"Seol","year":"1995","journal-title":"Mol. Endocrinol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104333_bib0255","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","article-title":"Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR","volume":"3","author":"Wang","year":"1999","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.phrs.2019.104333_bib0260","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0265","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1194\/jlr.M500417-JLR200","article-title":"FXR regulates organic solute transporters \u03b1 and \u03b2 in the adrenal gland, kidney, and intestine","volume":"47","author":"Lee","year":"2006","journal-title":"J. Lipid Res."},{"issue":"16","key":"10.1016\/j.phrs.2019.104333_bib0270","doi-asserted-by":"crossref","first-page":"11039","DOI":"10.1074\/jbc.M510258200","article-title":"The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice","volume":"281","author":"Cariou","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.phrs.2019.104333_bib0275","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.2337\/db06-1642","article-title":"Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy","volume":"56","author":"Jiang","year":"2007","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0280","first-page":"187","article-title":"Bile acids as novel pharmacological agents: the interplay between gene polymorphisms, epigenetic factors and drug response","volume":"23","author":"Pavlovic","year":"2017","journal-title":"Curr. Pharm. Des."},{"issue":"10","key":"10.1016\/j.phrs.2019.104333_bib0285","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.0000178994.21828.a7","article-title":"The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism","volume":"25","author":"Claudel","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0290","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1021\/mp060010s","article-title":"Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations","volume":"3","author":"Zollner","year":"2006","journal-title":"Mol. Pharm."},{"issue":"30","key":"10.1016\/j.phrs.2019.104333_bib0295","doi-asserted-by":"crossref","first-page":"27703","DOI":"10.1074\/jbc.M302128200","article-title":"Farnesoid X receptor regulates bile acid-amino acid conjugation","volume":"278","author":"Pircher","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2019.104333_bib0300","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab."},{"issue":"8","key":"10.1016\/j.phrs.2019.104333_bib0305","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bbadis.2010.12.021","article-title":"Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease","volume":"1812","author":"Claudel","year":"2011","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0310","doi-asserted-by":"crossref","first-page":"G476","DOI":"10.1152\/ajpgi.00430.2005","article-title":"The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-\u03b1 and-\u03b2 genes","volume":"290","author":"Landrier","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104333_bib0315","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2011.10.028","article-title":"Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis","volume":"142","author":"Modica","year":"2012","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.phrs.2019.104333_bib0320","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1210\/en.2004-0367","article-title":"Modulation of metabolic syndrome by fibroblast growth factor 19 (FGF19)?","volume":"145","author":"Strack","year":"2004","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.phrs.2019.104333_bib0325","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1248\/bpb.34.1885","article-title":"Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice","volume":"34","author":"Miyata","year":"2011","journal-title":"Biol. Pharm. Bull."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0330","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.phrs.2019.104333_bib0335","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1507\/endocrj.K07E-103","article-title":"Molecular basis of endocrine regulation by orphan nuclear receptor Small Heterodimer Partner","volume":"55","author":"Chanda","year":"2008","journal-title":"Endocr. J."},{"issue":"5","key":"10.1016\/j.phrs.2019.104333_bib0340","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.2337\/diabetes.52.5.1276","article-title":"Genetic variation in the small heterodimer partner gene and young-onset type 2 diabetes, obesity, and birth weight in UK subjects","volume":"52","author":"Mitchell","year":"2003","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.phrs.2019.104333_bib0345","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1073\/pnas.98.2.575","article-title":"Mutations in the small heterodimer partner gene are associated with mild obesity in Japanese subjects","volume":"98","author":"Nishigori","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"10","key":"10.1016\/j.phrs.2019.104333_bib0350","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.phrs.2019.104333_bib0355","doi-asserted-by":"crossref","first-page":"E716","DOI":"10.1152\/ajpendo.00355.2005","article-title":"Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters","volume":"290","author":"Bilz","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"22","key":"10.1016\/j.phrs.2019.104333_bib0360","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1101\/gad.844900","article-title":"Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXR\u03b1 and LXR\u03b2","volume":"14","author":"Repa","year":"2000","journal-title":"Genes Dev."},{"issue":"9","key":"10.1016\/j.phrs.2019.104333_bib0365","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.phrs.2019.104333_bib0370","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1210\/me.2002-0120","article-title":"Pineda Torra is, Claudel T, Duval C, Kosykh V, Fruchart J-C, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor \u03b1 gene via activation of the farnesoid X receptor","volume":"17","year":"2003","journal-title":"Mol. Endocrinol."},{"issue":"21-22","key":"10.1016\/j.phrs.2019.104333_bib0375","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.cca.2010.08.003","article-title":"Triglycerides and gallstone formation","volume":"411","author":"Smelt","year":"2010","journal-title":"Clin. Chim. Acta"},{"issue":"22","key":"10.1016\/j.phrs.2019.104333_bib0380","doi-asserted-by":"crossref","first-page":"23158","DOI":"10.1074\/jbc.M314322200","article-title":"Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1","volume":"279","author":"Yamagata","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2019.104333_bib0385","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0006-291X(02)02550-0","article-title":"Identification of membrane-type receptor for bile acids (M-BAR)","volume":"298","author":"Maruyama","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.phrs.2019.104333_bib0390","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1074\/jbc.M209706200","article-title":"AG protein-coupled receptor responsive to bile acids","volume":"278","author":"Kawamata","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.104333_bib0395","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mam.2017.01.006","article-title":"Bile acids and their receptors","volume":"56","author":"Martinot","year":"2017","journal-title":"Mol. Aspects Med."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0400","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2009.08.001","article-title":"TGR5-mediated bile acid sensing controls glucose homeostasis","volume":"10","author":"Thomas","year":"2009","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0405","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbrc.2012.09.104","article-title":"Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic \u03b2 cells","volume":"427","author":"Kumar","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.phrs.2019.104333_bib0410","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.24525","article-title":"The G\u2010Protein\u2010coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light\u2010chain enhancer of activated B cells (NF\u2010\u03baB) in mice","volume":"54","author":"Wang","year":"2011","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.phrs.2019.104333_bib0415","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cmet.2011.11.006","article-title":"TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading","volume":"14","author":"Pols","year":"2011","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.phrs.2019.104333_bib0420","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1084\/jem.20171965","article-title":"Bile acids in glucose metabolism in health and disease","volume":"215","author":"Shapiro","year":"2018","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.phrs.2019.104333_bib0425","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/S0960-894X(03)00281-6","article-title":"Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR)","volume":"13","author":"Costantino","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"18","key":"10.1016\/j.phrs.2019.104333_bib0430","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/jm049904b","article-title":"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure\u2212 activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid","volume":"47","author":"Pellicciari","year":"2004","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.phrs.2019.104333_bib0435","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6\u03b1-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104333_bib0440","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(10)60004-9","article-title":"2 Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? an international study evaluating the addition of INT-747 to ursodeoxycholic acid","volume":"52","author":"Mason","year":"2010","journal-title":"J. Hepatol."},{"issue":"20","key":"10.1016\/j.phrs.2019.104333_bib0445","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1021\/jm501273r","article-title":"Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands","volume":"57","author":"Festa","year":"2014","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2019.104333_bib0450","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1124\/mol.110.064501","article-title":"Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist","volume":"78","author":"Rizzo","year":"2010","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104333_bib0455","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT\u2010767 reduces liver injury in the Mdr2\u2212\/\u2212(Abcb4\u2212\/\u2212) mouse cholangiopathy model by promoting biliary HCO output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.phrs.2019.104333_bib0460","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1097-2765(03)00112-6","article-title":"Structural basis for bile acid binding and activation of the nuclear receptor FXR","volume":"11","author":"Mi","year":"2003","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0465","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbrc.2005.11.027","article-title":"5\u03b1-Bile alcohols function as farnesoid X receptor antagonists","volume":"339","author":"Nishimaki-Mogami","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.phrs.2019.104333_bib0470","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1194\/jlr.M400102-JLR200","article-title":"Identification of intermediates in the bile acid synthetic pathway as ligands for the farnesoid X receptor","volume":"45","author":"Nishimaki-Mogami","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2019.104333_bib0475","doi-asserted-by":"crossref","first-page":"16605","DOI":"10.1038\/srep16605","article-title":"Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism","volume":"5","author":"Di Leva","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2019.104333_bib0480","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fphar.2017.00162","article-title":"Targeting bile acid receptors: discovery of a potent and selective farnesoid X receptor agonist as a new lead in the pharmacological approach to liver diseases","volume":"8","author":"Festa","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104333_bib0485","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1021\/jm7015864","article-title":"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure\u2212 activity relationships, and molecular modeling studies","volume":"51","author":"Sato","year":"2008","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.phrs.2019.104333_bib0490","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1517\/13543776.2012.733000","article-title":"Patented TGR5 modulators: a review (2006\u2013present)","volume":"22","author":"Gioiello","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"issue":"18","key":"10.1016\/j.phrs.2019.104333_bib0495","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1021\/jm500889f","article-title":"Modification on ursodeoxycholic acid (UDCA) scaffold. Discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1)","volume":"57","author":"Sepe","year":"2014","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0500","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/jm401873d","article-title":"Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors","volume":"57","author":"D\u2019Amore","year":"2014","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.phrs.2019.104333_bib0505","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.bcp.2013.08.015","article-title":"Bile acid receptors in non-alcoholic fatty liver disease","volume":"86","author":"Li","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.phrs.2019.104333_bib0510","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4155\/fmc.15.54","article-title":"Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application","volume":"7","author":"Sepe","year":"2015","journal-title":"Future Med. Chem."},{"issue":"17","key":"10.1016\/j.phrs.2019.104333_bib0515","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1021\/jm0582221","article-title":"Farnesoid X receptor: from structure to potential clinical applications","volume":"48","author":"Pellicciari","year":"2005","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.phrs.2019.104333_bib0520","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0525","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"issue":"9972","key":"10.1016\/j.phrs.2019.104333_bib0530","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0535","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0540","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/apt.12999","article-title":"The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid","volume":"41","author":"Walters","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2019.104333_bib0545","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.M081935","article-title":"FXR activation by obeticholic acid or non-steroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver","author":"Papazyan","year":"2018","journal-title":"J. Lipid Res."},{"issue":"7","key":"10.1016\/j.phrs.2019.104333_bib0550","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1172\/JCI0214505","article-title":"Bile acid-activated nuclear receptor FXR suppresses apolipoprotein AI transcription via a negative FXR response element","volume":"109","author":"Claudel","year":"2002","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.phrs.2019.104333_bib0555","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1194\/jlr.M070888","article-title":"Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters","volume":"58","author":"Dong","year":"2017","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0560","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-95-3-257","article-title":"Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the national cooperative gallstone study: a controlled trial of efficacy and safety","volume":"95","author":"Schoenfield","year":"1981","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.104333_bib0565","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/S0168-8278(16)00372-X","article-title":"Regenerate: a phase 3, double-blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis","volume":"64","author":"Ratziu","year":"2016","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0570","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hep4.1013","article-title":"Update on pharmacotherapies for cholestatic liver disease","volume":"1","author":"Ali","year":"2017","journal-title":"Hepatol Commun."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0575","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000454904","article-title":"Nor-ursodeoxycholic acid as a novel therapeutic approach for cholestatic and metabolic liver diseases","volume":"35","author":"Halilbasic","year":"2017","journal-title":"Dig. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0580","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104333_bib0585","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jhep.2013.01.026","article-title":"Differential effects of norUDCA and UDCA in obstructive cholestasis in mice","volume":"58","author":"Fickert","year":"2013","journal-title":"J. Hepatol."},{"issue":"15","key":"10.1016\/j.phrs.2019.104333_bib0590","doi-asserted-by":"crossref","first-page":"8897","DOI":"10.1073\/pnas.151136298","article-title":"NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension","volume":"98","author":"Fiorucci","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.phrs.2019.104333_bib0595","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1527-3466.2004.tb00136.x","article-title":"Treatment of portal hypertension with NCX\u20101000, a liver\u2010specific NO donor. A review of its current status","volume":"22","author":"Fiorucci","year":"2004","journal-title":"Cardiovasc. Drug Rev."},{"issue":"5","key":"10.1016\/j.phrs.2019.104333_bib0600","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1073\/pnas.041603898","article-title":"An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity","volume":"98","author":"Fiorucci","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"5","key":"10.1016\/j.phrs.2019.104333_bib0605","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ajg.2009.661","article-title":"NCX-1000, a nitric oxide\u2013releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study","volume":"105","author":"Berzigotti","year":"2010","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104333_bib0610","first-page":"392","article-title":"A novel liver-targeted nitric oxide donor UDCA-Thr-NO protects against cirrhosis and portal hypertension","volume":"10","author":"Sun","year":"2018","journal-title":"Am. J. Transl. Res."},{"issue":"24","key":"10.1016\/j.phrs.2019.104333_bib0615","doi-asserted-by":"crossref","first-page":"7958","DOI":"10.1021\/jm901390p","article-title":"Discovery of 6\u03b1-ethyl-23 (S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity","volume":"52","author":"Pellicciari","year":"2009","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0620","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2010.12.008","article-title":"NF-\u03baB, inflammation, and metabolic disease","volume":"13","author":"Baker","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2019.104333_bib0625","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M112.446575","article-title":"Bile-acid receptor activation modulates hepatic monocyte activity and improves non-alcoholic fatty liver disease","author":"McMahan","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.phrs.2019.104333_bib0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108270","article-title":"Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis","volume":"9","author":"Miyazaki-Anzai","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0635","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/j.gastro.2011.09.051","article-title":"Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury","volume":"142","author":"Moustafa","year":"2012","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0640","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.2010.223834","article-title":"Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis","volume":"60","author":"Beraza","year":"2011","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.phrs.2019.104333_bib0645","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2014.11.020","article-title":"24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis","volume":"62","author":"Sombetzki","year":"2015","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0650","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF03190984","article-title":"Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3\u03b1, 7\u03b1-dihydroxy-12-0X0-5\u03b2-cholanate, in healthy and diabetic rats","volume":"32","author":"Mikov","year":"2007","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.phrs.2019.104333_bib0655","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/sj.emboj.7601049","article-title":"Endocrine functions of bile acids","volume":"25","author":"Houten","year":"2006","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0660","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000282091","article-title":"Bile acids as regulators of hepatic lipid and glucose metabolism","volume":"28","author":"Trauner","year":"2010","journal-title":"Dig. Dis."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0665","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s13318-017-0441-y","article-title":"Potential applications of gliclazide in treating type 1 diabetes mellitus: formulation with bile acids and probiotics","volume":"43","author":"Mikov","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.phrs.2019.104333_bib0670","first-page":"532","article-title":"Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats","volume":"60","author":"Al-Salami","year":"2008","journal-title":"Pharmacol. Rep."},{"issue":"4","key":"10.1016\/j.phrs.2019.104333_bib0675","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3109\/03639045.2015.1067626","article-title":"The influence of bile salts on the distribution of simvastatin in the octanol\/buffer system","volume":"42","author":"\u0110ani\u0107","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"2","key":"10.1016\/j.phrs.2019.104333_bib0680","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF03191024","article-title":"Influence of sodium monoketocholate on the hypolipidemic activity of lovastatin in healthy and diabetic rats","volume":"33","author":"Kojic-Damjanov","year":"2008","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0685","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF03191110","article-title":"The influence of 3\u03b1, 7\u03b1-dihydroxy-12-keto-5\u03b2-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes","volume":"33","author":"Mikov","year":"2008","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0690","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF03191014","article-title":"Effect of stevioside and sodium salt of monoketocholic acid on glycemia in normoglycemic and diabetic rats","volume":"33","author":"Raskovic","year":"2008","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.phrs.2019.104333_bib0695","series-title":"Bile Acids and Their Derivatives As Glycoregulatory Agents","author":"Miljkovic","year":"2000"},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0700","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0031-9384(04)00348-8","article-title":"Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans","volume":"83","author":"Stockhorst","year":"2004","journal-title":"Physiol. Behav."},{"issue":"3","key":"10.1016\/j.phrs.2019.104333_bib0705","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2337\/db14-0685","article-title":"Intranasal insulin suppresses endogenous glucose production in humans compared with placebo in the presence of similar venous insulin concentrations","volume":"64","author":"Dash","year":"2015","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.phrs.2019.104333_bib0710","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s13318-011-0060-y","article-title":"Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats","volume":"37","author":"Al-Salami","year":"2012","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0715","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF03191014","article-title":"Effect of stevioside and sodium salt of monoketocholic acid on glycemia in normoglycemic and diabetic rats","volume":"33","author":"Ra\u0161kovi\u0107","year":"2008","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.phrs.2019.104333_bib0720","series-title":"Composition and Uses Thereof","author":"Mikov","year":"2009"},{"issue":"1","key":"10.1016\/j.phrs.2019.104333_bib0725","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1078\/0944-7113-00081","article-title":"Stevioside induces antihyperglycaemic, insulinotropic and glucagonostatic effects in vivo: studies in the diabetic Goto-Kakizaki (GK) rats","volume":"9","author":"Jeppesen","year":"2002","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phrs.2019.104333_bib0730","series-title":"Composition for the Control of Cholesterol Levels","author":"Mikov","year":"2009"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819302786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819302786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:05:34Z","timestamp":1760911534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819302786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":146,"alternative-id":["S1043661819302786"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104333","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Semisynthetic bile acids: a new therapeutic option for metabolic syndrome","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104333"}}